SLC7A11 and Friedreich ataxia: However, given the recent FDA approval of omaveloxolone for FRDA (another condition to which ferroptosis is a known pathology), our data showing normalization of ferroptotic features such as SLC7A11 supports exploration of this pharmaceutical for individuals affected by FDXR-related disease.